Adjust Font Sizing:

Clinical Update Webinar Series

Last year on our online platforms, webinars, support groups and virtual Annual Conference, we listened and heard about what content matters to you. In response, we developed monthly clinical updates for you to engage through our emails, e-news and social media platforms.
Narcolepsy Network is delighted to announce that we will be hosting periodic virtual Clinical Update Webinar events. You will have the opportunity to learn different perspectives from clinicians, researchers and industry providers.  

Join us on September 13, at 8:00 PM (Eastern) for the second viewing of our August  Clinical Update webinar:  

“Update from Avadel on Investigational Clinical Treatment”


In this pre-recorded webinar, Avadel’s Vice President of Medical and Clinical Affairs Dr. Jennifer Gudeman explains the recent FDA tentative approval of LUMRYZ™ (sodium oxybate) for extended-release oral suspension, an investigational narcolepsy clinical treatment (formerly known as FT218), and addresses questions from the community that were submitted in advance of the original webinar on August 10. 



Dr. Jennifer Gudeman was appointed Vice President, Medical and Clinical Affairs, in December 2020. Prior to joining Avadel, Jennifer was Vice President, Medical Affairs, at AMAG Pharmaceuticals, overseeing a team of medical science liaisons and scientific communications. Prior to her time at AMAG Pharmaceuticals, she was Director of Medical Affairs at Lumara Health, a specialty branded pharmaceutical company focused on women’s health, and previously served at Mallinckrodt Pharmaceuticals. During her career, she has led or contributed to six commercial product launches and three clinical development programs, as well as led interactions with medical societies and patient advocacy organizations to help ensure that commercial medications fulfill their clinically proven therapeutic benefits to patients and providers. Jennifer has published numerous peer-reviewed papers and provided domestic and international presentations on partnership with industry for drug development in high-risk pregnancies. She graduated summa cum laude with a bachelor’s degree in pharmacy and magna cum laude with a doctorate in pharmacy from St. Louis College of Pharmacy.


Erica Jessie is a Sr. Medical Science Liaison in Medical Affairs.  In this role, Erica is responsible for conducting scientific exchange with key medical experts, engaging US Payer decision makers and interpreting medical insights for Avadel research.  Erica comes to Avadel with over 25 years of experience in clinical operations, medical affairs and HEOR/Market Access. 

In her spare time, Erica is an active volunteer with Big Brother Big Sister of Greater Charlotte and The Bulb Mobile Market supporting efforts to provide free, fresh produce to food insecure areas in her region.  Erica resides in Charlotte, NC and will be covering multiple territories.